AAV gene delivery to the spinal cord: serotypes, methods, candidate diseases, and clinical trials

References

• Janson C, McPhee S, Bilaniuk L, et al. Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain. Hum Gene Ther. 2002 Jul 20;13(11):1391–1412.
   PubMed Web of Science ®Google Scholar
• Azzouz M, Hottinger A, Paterna JC, et al. Increased motoneuron survival and improved neuromuscular function in transgenic ALS mice after intraspinal injection of an adeno-associated virus encoding Bcl-2. Hum Mol Genet. 2000 Mar 22;9(5):803–811.
   PubMed Web of Science ®Google Scholar
• Lepore AC, Haenggeli C, Gasmi M, et al. Intraparenchymal spinal cord delivery of adeno-associated virus IGF-1 is protective in the SOD1G93A model of ALS. Brain Res. 2007 Dec 14;1185:256–265.
   PubMed Web of Science ®Google Scholar
• Franz CK, Federici T, Yang J, et al. Intraspinal cord delivery of IGF-I mediated by adeno-associated virus 2 is neuroprotective in a rat model of familial ALS. Neurobiol Dis. 2009 Mar;33(3):473–481.
   PubMed Web of Science ®Google Scholar
• Gene transfer clinical trial for spinal muscular atrophy type 1. Available from: https://ClinicalTrials.gov/show/NCT02122952.  [Last accessed 27 November 2017].
   Google Scholar
• Intrathecal Administration of scAAV9/JeT-GAN for the Treatment of Giant Axonal Neuropathy. Available from: https://ClinicalTrials.gov/show/NCT02362438.  [Last accessed 27 November 2017].
   Google Scholar
• McCown TJ. Adeno-associated virus (AAV) vectors in the CNS. Curr Gene Ther. 2011 Jun;11(3):181–188.
   PubMed Web of Science ®Google Scholar
• Lisowski L, Tay SS, Alexander IE. Adeno-associated virus serotypes for gene therapeutics. Curr Opin Pharmacol. 2015 Oct;24:59–67.
   PubMed Web of Science ®Google Scholar
• Burger C, Gorbatyuk OS, Velardo MJ, et al. Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Mol Ther: J Am Soc Gene Ther. 2004 Aug;10(2):302–317.
   PubMed Web of Science ®Google Scholar
• Hollis ER 2nd, Kadoya K, Hirsch M, et al. Efficient retrograde neuronal transduction utilizing self-complementary AAV1. Mol Ther: J Am Soc Gene Ther. 2008 Feb;16(2):296–301.
   PubMed Web of Science ®Google Scholar
• Cearley CN, Vandenberghe LH, Parente MK, et al. Expanded repertoire of AAV vector serotypes mediate unique patterns of transduction in mouse brain. Mol Ther: J Am Soc Gene Ther. 2008 Oct;16(10):1710–1718.
   PubMed Web of Science ®Google Scholar
• Snyder BR, Gray SJ, Quach ET, et al. Comparison of adeno-associated viral vector serotypes for spinal cord and motor neuron gene delivery. Hum Gene Ther. 2011 Sep;22(9):1129–1135.
   PubMed Web of Science ®Google Scholar
• Petrosyan HA, Alessi V, Singh V, et al. Transduction efficiency of neurons and glial cells by AAV-1, -5, -9, -rh10 and -hu11 serotypes in rat spinal cord following contusion injury. Gene Ther. 2014 Dec;21(12):991–1000.
   PubMed Web of Science ®Google Scholar
• Sorrentino NC, Maffia V, Strollo S, et al. A comprehensive map of CNS transduction by eight recombinant adeno-associated virus serotypes upon cerebrospinal fluid administration in pigs. Mol Ther: J Am Soc Gene Ther. 2016 Feb;24(2):276–286.
   PubMed Web of Science ®Google Scholar
• Hutson TH, Verhaagen J, Yanez-Munoz RJ, et al. Corticospinal tract transduction: a comparison of seven adeno-associated viral vector serotypes and a non-integrating lentiviral vector. Gene Ther. 2012 Jan;19(1):49–60.
   PubMed Web of Science ®Google Scholar
• Davidson BL, Stein CS, Heth JA, et al. Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3428–3432.
   PubMed Web of Science ®Google Scholar
• Foust KD, Flotte TR, Reier PJ, et al. Recombinant adeno-associated virus-mediated global anterograde delivery of glial cell line-derived neurotrophic factor to the spinal cord: comparison of rubrospinal and corticospinal tracts in the rat. Hum Gene Ther. 2008 Jan;19(1):71–82.
   PubMed Web of Science ®Google Scholar
• Gransee HM, Zhan WZ, Sieck GC, et al. Targeted delivery of TrkB receptor to phrenic motoneurons enhances functional recovery of rhythmic phrenic activity after cervical spinal hemisection. PloS One. 2013;8(5):e64755.
   PubMed Web of Science ®Google Scholar
• Martinez-Galvez G, Zambrano JM, Diaz Soto JC, et al. TrkB gene therapy by adeno-associated virus enhances recovery after cervical spinal cord injury. Exp Neurol. 2016;276:31–40.
   PubMed Web of Science ®Google Scholar
• Zheng H, Qiao C, Wang C-H, et al. Efficient retrograde transport of adeno-associated virus type 8 to spinal cord and dorsal root ganglion after vector delivery in muscle. Hum Gene Ther. 2010 Dec 17;21(1):87–97.
   PubMed Web of Science ®Google Scholar
• Jacques SJ, Ahmed Z, Forbes A, et al. AAV8(gfp) preferentially targets large diameter dorsal root ganglion neurones after both intra-dorsal root ganglion and intrathecal injection. Mol Cell Neurosci. 2012 Apr;49(4):464–474.
   PubMed Web of Science ®Google Scholar
• Foust KD, Wang X, McGovern VL, et al. Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat Biotechnol. 2010 Mar;28(3):271–274.
   PubMed Web of Science ®Google Scholar
• Bevan AK, Hutchinson KR, Foust KD, et al. Early heart failure in the SMNDelta7 model of spinal muscular atrophy and correction by postnatal scAAV9-SMN delivery. Hum Mol Genet. 2010 Oct 15;19(20):3895–3905.
   PubMed Web of Science ®Google Scholar
• Dominguez E, Marais T, Chatauret N, et al. Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice. Hum Mol Genet. 2011 Feb 15;20(4):681–693.
   PubMed Web of Science ®Google Scholar
• Little D, Valori CF, Mutsaers CA, et al. PTEN depletion decreases disease severity and modestly prolongs survival in a mouse model of spinal muscular atrophy. Mol Ther:J Am Soc Gene Ther. 2015 Feb;23(2):270–277.
   PubMed Web of Science ®Google Scholar
• Homs J, Pagès G, Ariza L, et al. Intrathecal administration of IGF-I by AAVrh10 improves sensory and motor deficits in a mouse model of diabetic neuropathy. Molecul Ther Meth Clin Develop. 2014 Jan 15;1:7.
   PubMed Web of Science ®Google Scholar
• Tanguy Y, Biferi MG, Besse A, et al. Systemic AAVrh10 provides higher transgene expression than AAV9 in the brain and the spinal cord of neonatal mice. Front Mol Neurosci. 2015;8:36.
   PubMed Web of Science ®Google Scholar
• Teng Q, Federici T, Boulis N. Viral vector axonal uptake and retrograde transport: mechanisms and applications. In: Kaplitt M, During M, editors.. Gene therapy of the central nervous system: from bench to bedside. Elsevier; San Diego, CA, 2006. p. 249–267.
   Google Scholar
• Boulis NM, Noordmans AJ, Song DK, et al. Adeno-associated viral vector gene expression in the adult rat spinal cord following remote vector delivery. Neurobiol Dis. 2003 Dec;14(3):535–541.
   PubMed Web of Science ®Google Scholar
• Boulis NM, Willmarth NE, Song DK, et al. Intraneural colchicine inhibition of adenoviral and adeno-associated viral vector remote spinal cord gene delivery. Neurosurgery. 2003 Feb;52(2):381–7;discussion 87.
   PubMed Web of Science ®Google Scholar
• Towne C, Schneider BL, Kieran D, et al. Efficient transduction of non-human primate motor neurons after intramuscular delivery of recombinant AAV serotype 6. Gene Ther. 2010 Jan;17(1):141–146.
   PubMed Web of Science ®Google Scholar
• McCarty DM, Monahan PE, Samulski RJ. Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther. 2001 Aug;8(16):1248–1254.
   PubMed Web of Science ®Google Scholar
• Benkhelifa-Ziyyat S, Besse A, Roda M, et al. Intramuscular scAAV9-SMN injection mediates widespread gene delivery to the spinal cord and decreases disease severity in SMA mice. Mol Ther: J Am Soc Gene Ther. 2013 Feb;21(2):282–290.
   PubMed Web of Science ®Google Scholar
• Kaspar BK, Llado J, Sherkat N, et al. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science (New York, NY). 2003 Aug 08;301(5634):839–842.
   Google Scholar
• Miller TM, Kaspar BK, Kops GJ, et al. Virus-delivered small RNA silencing sustains strength in amyotrophic lateral sclerosis. Ann Neurol. 2005 May;57(5):773–776.
   PubMed Web of Science ®Google Scholar
• Fischer LR, Culver DG, Tennant P, et al. Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Exp Neurol. 2004 Feb;185(2):232–240.
   PubMed Web of Science ®Google Scholar
• Bilsland LG, Sahai E, Kelly G, et al. Deficits in axonal transport precede ALS symptoms in vivo. Proc Natl Acad Sci U S A. 2010 Nov 23;107(47):20523–20528.
   PubMed Web of Science ®Google Scholar
• Foust KD, Nurre E, Montgomery CL, et al. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol. 2009 Jan;27(1):59–65.
   PubMed Web of Science ®Google Scholar
• Duque S, Joussemet B, Riviere C, et al. Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol Ther:J Am Soc Gene Ther. 2009 Jul;17(7):1187–1196.
   PubMed Web of Science ®Google Scholar
• Wang DB, Dayton RD, Henning PP, et al. Expansive gene transfer in the rat CNS rapidly produces amyotrophic lateral sclerosis relevant sequelae when TDP-43 is overexpressed. Mol Ther:J Am Soc Gene Ther. 2010 Dec;18(12):2064–2074.
   PubMed Web of Science ®Google Scholar
• Zhang H, Yang B, Mu X, et al. Several rAAV vectors efficiently cross the blood-brain barrier and transduce neurons and astrocytes in the neonatal mouse central nervous system. Mol Ther:J Am Soc Gene Ther. 2011 Aug;19(8):1440–1448.
   PubMed Web of Science ®Google Scholar
• Gray SJ, Matagne V, Bachaboina L, et al. Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates. Mol Ther:J Am Soc Gene Ther. 2011 Jun;19(6):1058–1069.
   PubMed Web of Science ®Google Scholar
• Bevan AK, Duque S, Foust KD, et al. Systemic gene delivery in large species for targeting spinal cord, brain, and peripheral tissues for pediatric disorders. Mol Ther:J Am Soc Gene Ther. 2011 Nov;19(11):1971–1980.
   PubMed Web of Science ®Google Scholar
• Mendell JR, Al-Zaidy S, Shell R, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 2017 Nov 02;377(18):1713–1722.
   PubMed Web of Science ®Google Scholar
• Gray SJ, Nagabhushan Kalburgi S, McCown TJ, et al. Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates. Gene Ther. 2013 Apr;20(4):450–459.
   PubMed Web of Science ®Google Scholar
• Passini MA, Bu J, Richards AM, et al. Translational fidelity of intrathecal delivery of self-complementary AAV9-survival motor neuron 1 for spinal muscular atrophy. Hum Gene Ther. 2014 Jul;25(7):619–630.
   PubMed Web of Science ®Google Scholar
• Samaranch L, Salegio EA, San Sebastian W, et al. Strong cortical and spinal cord transduction after AAV7 and AAV9 delivery into the cerebrospinal fluid of nonhuman primates. Hum Gene Ther. 2013 May;24(5):526–532.
   PubMed Web of Science ®Google Scholar
• Bucher T, Dubreil L, Colle MA, et al. Intracisternal delivery of AAV9 results in oligodendrocyte and motor neuron transduction in the whole central nervous system of cats. Gene Ther. 2014 May;21(5):522–528.
   PubMed Web of Science ®Google Scholar
• Dirren E, Towne CL, Setola V, et al. Intracerebroventricular injection of adeno-associated virus 6 and 9 vectors for cell type-specific transgene expression in the spinal cord. Hum Gene Ther. 2014 Feb;25(2):109–120.
   PubMed Web of Science ®Google Scholar
• Borel F, Gernoux G, Cardozo B, et al. Therapeutic rAAVrh10 mediated SOD1 silencing in adult SOD1(G93A) mice and nonhuman primates. Hum Gene Ther. 2016 Dec 28;27(1):19–31.
   PubMed Web of Science ®Google Scholar
• Hinderer C, Bell P, Louboutin JP, et al. Neonatal systemic AAV induces tolerance to CNS gene therapy in MPS I dogs and nonhuman primates. Mol Ther:J Am Soc Gene Ther. 2015 Aug;23(8):1298–1307.
   PubMed Web of Science ®Google Scholar
• Storek B, Reinhardt M, Wang C, et al. Sensory neuron targeting by self-complementary AAV8 via lumbar puncture for chronic pain. Proc Natl Acad Sci U S A. 2008 Jan 22;105(3):1055–1060.
   PubMed Web of Science ®Google Scholar
• Vulchanova L, Schuster DJ, Belur LR, et al. Differential adeno-associated virus mediated gene transfer to sensory neurons following intrathecal delivery by direct lumbar puncture. Molecular Pain. 2010 May;28(6):31.
   Google Scholar
• Guo Y, Wang D, Qiao T, et al. A single injection of recombinant adeno-associated virus into the lumbar cistern delivers transgene expression throughout the whole spinal cord. Mol Neurobiol. 2016 Jul;53(5):3235–3248.
   PubMed Web of Science ®Google Scholar
• Federici T, Taub JS, Baum GR, et al. Robust spinal motor neuron transduction following intrathecal delivery of AAV9 in pigs. Gene Ther. 2012 Aug;19(8):852–859.
   PubMed Web of Science ®Google Scholar
• Bucher T, Colle MA, Wakeling E, et al. scAAV9 intracisternal delivery results in efficient gene transfer to the central nervous system of a feline model of motor neuron disease. Hum Gene Ther. 2013 Jul;24(7):670–682.
   PubMed Web of Science ®Google Scholar
• Samaranch L, San Sebastian W, Kells AP, et al. AAV9-mediated expression of a non-self protein in nonhuman primate central nervous system triggers widespread neuroinflammation driven by antigen-presenting cell transduction. Mol Ther:J Am Soc Gene Ther. 2014 Feb;22(2):329–337.
   PubMed Web of Science ®Google Scholar
• Meyer K, Ferraiuolo L, Schmelzer L, et al. Improving single injection CSF delivery of AAV9-mediated gene therapy for SMA: a dose-response study in mice and nonhuman primates. Mol Ther:J Am Soc Gene Ther. 2015 Mar;23(3):477–487.
   PubMed Web of Science ®Google Scholar
• Hinderer C, Bell P, Katz N, et al. Evaluation of intrathecal routes of administration for adeno-associated virus vectors in large animals. Hum Gene Ther. 2017 Aug 15.
   PubMed Web of Science ®Google Scholar
• Miyanohara A, Kamizato K, Juhas S, et al. Potent spinal parenchymal AAV9-mediated gene delivery by subpial injection in adult rats and pigs. Molecul Ther Meth Clin Develop. 2016;3:16046.
   PubMed Web of Science ®Google Scholar
• Riley J, Butler J, Park J, et al. Targeted spinal cord therapeutics delivery: stabilized platform and MER guidance validation. Stereotact Funct Neurosurg. 2007;86(2):67–74.
   PubMed Web of Science ®Google Scholar
• Federici T, Hurtig CV, Burks KL, et al. Surgical technique for spinal cord delivery of therapies: demonstration of procedure in gottingen minipigs. Journal Visual Exp: JoVE. 2012 Dec;07(70):e4371.
   Google Scholar
• Human spinal cord derived neural stem cell transplantation for the treatment of amyotrophic lateral sclerosis. Available from: https://ClinicalTrials.gov/show/NCT01348451. [Last accessed 27 November 2017].
   Google Scholar
• Dose escalation and safety study of human spinal cord derived neural stem cell transplantation for the treatment of amyotrophic lateral sclerosis. Available from: https://ClinicalTrials.gov/show/NCT01730716. [Last accessed 27 November 2017].
   Google Scholar
• Glass JD, Hertzberg VS, Boulis NM, et al. Transplantation of spinal cord-derived neural stem cells for ALS: analysis of phase 1 and 2 trials. Neurology. 2016 Jul 26;87(4):392–400.
   PubMed Web of Science ®Google Scholar
• Federici T, Riley J, Park J, et al. Preclinical safety validation of a stabilized viral vector direct injection approach to the cervical spinal cord. Clin Transl Sci. 2009 Apr;2(2):165–167.
   PubMed Web of Science ®Google Scholar
• Wang LJ, Lu YY, Muramatsu S, et al. Neuroprotective effects of glial cell line-derived neurotrophic factor mediated by an adeno-associated virus vector in a transgenic animal model of amyotrophic lateral sclerosis. J Neurosci: J Soc Neurosci. 2002 Aug 15;22(16):6920–6928.
   PubMed Web of Science ®Google Scholar
• Nanou A, Higginbottom A, Valori CF, et al. Viral delivery of antioxidant genes as a therapeutic strategy in experimental models of amyotrophic lateral sclerosis. Mol Ther: J Am Soc Gene Ther. 2013 Aug;21(8):1486–1496.
   PubMed Web of Science ®Google Scholar
• Yamashita T, Chai HL, Teramoto S, et al. Rescue of amyotrophic lateral sclerosis phenotype in a mouse model by intravenous AAV9-ADAR2 delivery to motor neurons. EMBO Mol Med. 2013 Nov;5(11):1710–1719.
   PubMed Web of Science ®Google Scholar
• Foust KD, Salazar DL, Likhite S, et al. Therapeutic AAV9-mediated suppression of mutant SOD1 slows disease progression and extends survival in models of inherited ALS. Mol Ther: J Am Soc Gene Ther. 2013 Dec;21(12):2148–2159.
   PubMed Web of Science ®Google Scholar
• Wang H, Yang B, Qiu L, et al. Widespread spinal cord transduction by intrathecal injection of rAAV delivers efficacious RNAi therapy for amyotrophic lateral sclerosis. Hum Mol Genet. 2014 Sep 18;23(3):668–681.
   PubMed Web of Science ®Google Scholar
• Patel P, Kriz J, Gravel M, et al. Adeno-associated virus–mediated delivery of a recombinant single-chain antibody against misfolded superoxide dismutase for treatment of amyotrophic lateral sclerosis. Mol Ther. 2014 Jan 07;22(3):498–510.
   PubMed Web of Science ®Google Scholar
• Dirren E, Aebischer J, Rochat C, et al. SOD1 silencing in motoneurons or glia rescues neuromuscular function in ALS mice. Ann Clin Transl Neurol. 2015 Jan 15;2(2):167–184.
   PubMed Web of Science ®Google Scholar
• Wang Y, Duan W, Wang W, et al. scAAV9-VEGF prolongs the survival of transgenic ALS mice by promoting activation of M2 microglia and the PI3K/Akt pathway. Brain Res. 2016 Oct 01;1648(Pt A):1–10.
   PubMed Web of Science ®Google Scholar
• Thomsen GM, Alkaslasi M, Vit JP, et al. Systemic injection of AAV9-GDNF provides modest functional improvements in the SOD1(G93A) ALS rat but has adverse side effects. Gene Ther. 2017 Mar 09;24(4):245–252.
   PubMed Web of Science ®Google Scholar
• Wang W, Duan W, Wang Y, et al. Intrathecal delivery of ssAAV9-DAO extends survival in SOD1G93A ALS mice. Neurochem Res. 2017 Apr;42(4):986–996.
   PubMed Web of Science ®Google Scholar
• Passini MA, Bu J, Roskelley EM, et al. CNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophy. J Clin Invest. 2010 Apr;120(4):1253–1264.
   PubMed Web of Science ®Google Scholar
• Ning K, Drepper C, Valori CF, et al. PTEN depletion rescues axonal growth defect and improves survival in SMN-deficient motor neurons. Hum Mol Genet. 2010 Aug 15;19(16):3159–3168.
   PubMed Web of Science ®Google Scholar
• Tsai LK, Chen CL, Ting CH, et al. Systemic administration of a recombinant AAV1 vector encoding IGF-1 improves disease manifestations in SMA mice. Mol Ther: J Am Soc Gene Ther. 2014 Aug;22(8):1450–1459.
   PubMed Web of Science ®Google Scholar
• Rindt H, Feng Z, Mazzasette C, et al. Astrocytes influence the severity of spinal muscular atrophy. Hum Mol Genet. 2015 Jul 15;24(14):4094–4102.
   PubMed Web of Science ®Google Scholar
• Kaifer KA, Villalon E, Osman EY, et al. Plastin-3 extends survival and reduces severity in mouse models of spinal muscular atrophy. JCI Insight. 2017 Mar 09;2(5):e89970.
   PubMed Web of Science ®Google Scholar
• Chen SL, Ma HI, Han JM, et al. dsAAV type 2-mediated gene transfer of MORS196A-EGFP into spinal cord as a pain management paradigm. Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):20096–20101.
   PubMed Web of Science ®Google Scholar
• Chen SL, Ma HI, Han JM, et al. Antinociceptive effects of morphine and naloxone in mu-opioid receptor knockout mice transfected with the MORS196A gene. J Biomed Sci. 2010 Apr 20;17:28.
   PubMed Web of Science ®Google Scholar
• Kao JH, Chen SL, Ma HI, et al. Intrathecal delivery of a mutant micro-opioid receptor activated by naloxone as a possible antinociceptive paradigm. J Pharmacol Exp Ther. 2010 Sep 01;334(3):739–745.
   PubMed Web of Science ®Google Scholar
• Lin Y, Roman K, Foust KD, et al. Glutamate transporter GLT-1 upregulation attenuates visceral nociception and hyperalgesia via spinal mechanisms not related to anti-inflammatory or probiotic effects. Pain Res Treat. 2011;2011:507029.
   PubMedGoogle Scholar
• Samad OA, Tan AM, Cheng X, et al. Virus-mediated shRNA knockdown of Na(v)1.3 in rat dorsal root ganglion attenuates nerve injury-induced neuropathic pain. Mol Ther:J Am Soc Gene Ther. 2013 Jan;21(1):49–56.
   PubMed Web of Science ®Google Scholar
• Hirai T, Enomoto M, Kaburagi H, et al. Intrathecal AAV serotype 9-mediated delivery of shRNA against TRPV1 attenuates thermal hyperalgesia in a mouse model of peripheral nerve injury. Mol Ther:J Am Soc Gene Ther. 2014 Feb;22(2):409–419.
   PubMed Web of Science ®Google Scholar
• Vicuna L, Strochlic DE, Latremoliere A, et al. The serine protease inhibitor SerpinA3N attenuates neuropathic pain by inhibiting T cell-derived leukocyte elastase. Nat Med. 2015 May;21(5):518–523.
   PubMed Web of Science ®Google Scholar
• Falnikar A, Hala TJ, Poulsen DJ, et al. GLT1 overexpression reverses established neuropathic pain-related behavior and attenuates chronic dorsal horn neuron activation following cervical spinal cord injury. Glia. 2016 Mar;64(3):396–406.
   PubMed Web of Science ®Google Scholar
• Qiu K, Falk DJ, Reier PJ, et al. Spinal delivery of AAV vector restores enzyme activity and increases ventilation in Pompe mice. Mol Ther: J Am Soc Gene Ther. 2012 Jan;20(1):21–27.
   PubMed Web of Science ®Google Scholar
• Federici T, Boulis NM. Gene therapy for amyotrophic lateral sclerosis. Neurobiol Dis. 2012 Nov;48(2):236–242.
   PubMed Web of Science ®Google Scholar
• Chiriboga CA, Swoboda KJ, Darras BT, et al. Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy. Neurology. 2016 Mar 08;86(10):890–897.
   PubMed Web of Science ®Google Scholar
• Talbot K, Tizzano EF. The clinical landscape for SMA in a new therapeutic era. Gene Ther. 2017 Jul 23;24:529–533.
   PubMed Web of Science ®Google Scholar
• Le TT, Pham LT, Butchbach ME, et al. SMNDelta7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN. Hum Mol Genet. 2005 Mar 15;14(6):845–857.
   PubMed Web of Science ®Google Scholar
• Duque SI, Arnold WD, Odermatt P, et al. A large animal model of spinal muscular atrophy and correction of phenotype. Ann Neurol. 2015 Mar;77(3):399–414.
   PubMed Web of Science ®Google Scholar
• Houlden H, Groves M, Miedzybrodzka Z, et al. New mutations, genotype phenotype studies and manifesting carriers in giant axonal neuropathy. J Neurol Neurosurg Psychiatry. 2007 Nov;78(11):1267–1270.
   PubMed Web of Science ®Google Scholar
• Mussche S, De Paepe B, Smet J, et al. Proteomic analysis in giant axonal neuropathy: new insights into disease mechanisms. Muscle Nerve. 2012 Aug;46(2):246–256.
   PubMed Web of Science ®Google Scholar
• Dequen F, Bomont P, Gowing G, et al. Modest loss of peripheral axons, muscle atrophy and formation of brain inclusions in mice with targeted deletion of gigaxonin exon 1. J Neurochem. 2008 Oct;107(1):253–264.
   PubMed Web of Science ®Google Scholar
• Ding J, Allen E, Wang W, et al. Gene targeting of GAN in mouse causes a toxic accumulation of microtubule-associated protein 8 and impaired retrograde axonal transport. Hum Mol Genet. 2006 May 01;15(9):1451–1463.
   PubMed Web of Science ®Google Scholar
• Ganay T, Boizot A, Burrer R, et al. Sensory-motor deficits and neurofilament disorganization in gigaxonin-null mice. Mol Neurodegener. 2011 Apr;12(6):25.
   Google Scholar
• Mussche S, Devreese B, Nagabhushan Kalburgi S, et al. Restoration of cytoskeleton homeostasis after gigaxonin gene transfer for giant axonal neuropathy. Hum Gene Ther. 2013 Feb;24(2):209–219.
   PubMed Web of Science ®Google Scholar
• Storek B, Harder NM, Banck MS, et al. Intrathecal long-term gene expression by self-complementary adeno-associated virus type 1 suitable for chronic pain studies in rats. Molecular Pain. 2006 Jan 30;2:4.
   PubMed Web of Science ®Google Scholar
• Foust KD, Poirier A, Pacak CA, et al. Neonatal intraperitoneal or intravenous injections of recombinant adeno-associated virus type 8 transduce dorsal root ganglia and lower motor neurons. Hum Gene Ther. 2008 Jan;19(1):61–70.
   PubMed Web of Science ®Google Scholar
• Pleticha J, Malkmus SA, Heilmann LF, et al. High cerebrospinal fluid levels of interleukin-10 attained by AAV in dogs. Gene Ther. 2015 Feb;22(2):202–208.
   PubMed Web of Science ®Google Scholar
• Eaton MJ, Blits B, Ruitenberg MJ, et al. Amelioration of chronic neuropathic pain after partial nerve injury by adeno-associated viral (AAV) vector-mediated over-expression of BDNF in the rat spinal cord. Gene Ther. 2002 Oct;9(20):1387–1395.
   PubMed Web of Science ®Google Scholar
• Milligan ED, Sloane EM, Langer SJ, et al. Controlling neuropathic pain by adeno-associated virus driven production of the anti-inflammatory cytokine, interleukin-10. Mol Pain. 2005 Feb 25;1:9.
   PubMed Web of Science ®Google Scholar
• Xu Y, Gu Y, Wu P, et al. Efficiencies of transgene expression in nociceptive neurons through different routes of delivery of adeno-associated viral vectors. Hum Gene Ther. 2003 Jun 10;14(9):897–906.
   PubMed Web of Science ®Google Scholar
• Elmallah MK, Falk DJ, Nayak S, et al. Sustained correction of motoneuron histopathology following intramuscular delivery of AAV in pompe mice. Mol Ther: J Am Soc Gene Ther. 2014 Apr;22(4):702–712.
   PubMed Web of Science ®Google Scholar
• Hordeaux J, Dubreil L, Robveille C, et al. Long-term neurologic and cardiac correction by intrathecal gene therapy in Pompe disease. Acta Neuropathol Comm. 2017 Sep 06;5(1):66.
   PubMedGoogle Scholar
• Perdomini M, Belbellaa B, Monassier L, et al. Prevention and reversal of severe mitochondrial cardiomyopathy by gene therapy in a mouse model of Friedreich’s ataxia. Nat Med. 2014 May;20(5):542–547.
   PubMed Web of Science ®Google Scholar
• Gerard C, Xiao X, Filali M, et al. An AAV9 coding for frataxin clearly improved the symptoms and prolonged the life of Friedreich ataxia mouse models. Molecul Ther Meth Clin Develop. 2014;1:14044.
   PubMed Web of Science ®Google Scholar
• AveXis presents results from phase 1 trial of AVXS-101 in SMA type 1 at the Annual Meeting of the American Academy of Neurology. AveXis, Inc; 2017. Available from: http://investors.avexis.com/phoenix.zhtml?c=254285&p=irol-newsArticle&ID=2264492. [Last accessed 27 November 2017]
   Google Scholar
• Gray SJ, Bailey RM, Bharucha-Goebel D, et al. Postmortem assessment of vector biodistribution in the first-in-human intrathecal scAAV9 gene therapy trial for giant axonal neuropathy. Washington, District of Columbia: American Society of Gene and Cell Therapy 20th Annual Meeting; 2017.
   Google Scholar